Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study

BMC Public Health

Research Article

Marcello Pagano¹  Bethany L Hedt¹  Ted Cohen² 

[1] Department of Biostatistics, Harvard School of Public Health, 677 Huntington Avenue, 02115, Boston, USA;Division of Global Health Equity, Brigham and Women's Hospital, 641 Huntington Avenue, 02115, Boston, USA;Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, 02115, Boston, USA;

关键词: Private Sector;    Public Sector;    Private Provider;    Private Practitioner;    Retreatment Case;   

DOI  :  10.1186/1471-2458-10-355

 received in 2009-11-04, accepted in 2010-06-21,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundAccurate assessment of the burden of drug-resistant TB requires systematic efforts to quantify its magnitude and trend. In approximately half the countries where resistance has been reported, estimates are based on surveys conducted in public sector facilities. However, in locations where a substantial fraction of TB cases seek care with private providers, these surveys may not accurately measure resistance in the entire population.MethodsWe describe a mathematical model to investigate biases associated with sampling only from public sector cases in India, where TB treatment is offered in both public and private sectors. We then propose and demonstrate a weighted estimator as an efficient method for including small numbers of cases from the private sector as a way to recover valid estimates of resistance in the population under study.ResultsWe find that public sector surveys rarely provide valid estimates of drug-resistance among new and retreatment cases. Further, the magnitude and direction of the bias are sensitive to many parameters describing the health-seeking behaviours and treatment outcomes of tuberculosis patients, disallowing simple adjustments to recover accurate estimates.ConclusionsIn locations where large numbers of tuberculosis patients are diagnosed and treated by private sector practitioners who are not typically included in drug resistance surveys, targeted surveys for assessing drug resistance are required to validly estimate resistance.

【 授权许可】

CC BY   
© Cohen et al; licensee BioMed Central Ltd. 2010